A Tail-Wagging FDA Opportunity 60 Degrees Pharmaceuticals just gave investors something to chew on. The company announced plans to seek MUMS (Minor Use in Minor Species) designation from the FDA for its tafenoquine-based treatment targeting acute canine babesiosis—a tick-borne disease that’s as nasty for dogs as Lyme is for humans. The application will be backed by three clinical studies on ARAKODA®, plus safety and manufacturing data. If approved, this could open a niche but meaningful market for SXTP, especially among veterinary specialists and pet owners desperate for effective treatments. 60 Degrees Pharmaceuticals Stock Price: What’s the Buzz? As of July 15, 2025, SXTP is trading at $0.79, holding steady in after-hours trading. That’s a 20% jump from its previous close, driven by investor optimism around the MUMS announcement. While the stock is still deep in penny territory, the surge shows that even small biotech plays can wag the market when news hits the right nerve. Why This Matters for SXTP’s Future Let’s be real—60 Degrees isn’t exactly Pfizer. But it’s carving out a niche in infectious disease treatments, with tafenoquine already in use for malaria prevention. Expanding into veterinary medicine could diversify its pipeline and revenue streams. Plus, the company has partnerships with institutions like Tufts Medical Center, and its babesiosis research has revealed that the disease may be 10x more prevalent than CDC estimates. That’s not just a stat—it’s a market signal. Final Thoughts: Is SXTP a Hidden Gem or Just a Fleeting Bark? SXTP’s price action shows how fast sentiment can shift in micro-cap biotech. The MUMS application isn’t a guaranteed win, but it’s a strategic move that could unlock new value. If you’re into speculative plays with upside potential (and don’t mind a little volatility), this one might be worth sniffing around. Just remember: in biotech, the leash is short and the risks are real. But sometimes, the underdog bites back.
How much money did you lose? I guess you bought it on 8 Apr 2025 when there was a major/big news. Lately the price movement and volume is so tiny. I have to use the scanning electron microscope to view it. Anyway ... Indeed it popped from $520 to $2. Come on ! Go to 1 cent faster!